Tscan Therapeutics Inc (TCRX) - News Archive

TScan Therapeutics: Strategic Participation in Investor Conferences Amid Mixed Market Performance TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology firm headquartered in Waltham, Massachusetts, is...

TScan Therapeutics Bold Financial Move: A 37% Premium Investment InfusionIn a striking display of investor confidence, TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced a $30 million registered direct offering, mark...

In an era where precision medicine continues to redefine therapeutic outcomes in oncology, TScan Therapeutics has emerged at the forefront of innovation, presenting compelling findings from its ongoing ALLOHA Phase 1 He...

TScan Therapeutics Receives FDA s RMAT Designation for Pioneering TCR-T Therapy Candidates TSC-100 and TSC-101 A Promising Leap Forward in the Treatment of Hematologic MalignanciesTScan Therapeutics has achieved a signi...

TScan Therapeutics Announces Extra Share Purchase, Drives Up Stock ValueTScan Therapeutics Inc. sees a boost in share value after the announcement that the underwriters of its recent public offering have exercised their...

TScan Therapeutics Raises $150.1 Million in Upsized Public Offering, Strengthening Position in TCR-T Cell Therapy MarketTScan Therapeutics, a clinical-stage biopharmaceutical company specializing in T cell receptor-engi...

TScan Therapeutics Raises $150 Million in Upsized Public Offering to Advance Cancer TherapiesTScan Therapeutics, a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapi...

WALTHAM, Mass., April 16, 2024 - TScan Therapeutics, a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies for cancer treatment, has recently announced the launch o...

The world of cancer immunotherapies is witnessing promising advancements with respect to T-Cell receptor therapies (TCR-T). At the forefront of such advancements is TScan Therapeutics, a biopharmaceutical company workin...

is pleased to report on the highly promising and groundbreaking Phase 1 clinical results presented by TScan Therapeutics at the prestigious 2024 Tandem Meetings of the American Society for Transplantation and Cellular T...

TScan Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer patients, is set to make groundbreaking strides in t...

TScan Therapeutics: Positive Initial Data from Phase 1 Heme Program at ASH Annual MeetingTScan Therapeutics Inc recently reported positive initial data from its Phase 1 heme program at the 65th American Society of Hemat...

The highly anticipated phase 1 clinical trial results for TScan Therapeutics experimental treatments, TSC-100 and TSC-101, were recently presented at the 65th American Society of Hematology Annual Meeting and Exposition...

IntroductionTScan Therapeutics, a clinical-stage biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies (TCR-T) for cancer treatment, has announced its plans to host a virtual key op...